Cargando…
不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究
OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antit...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343096/ https://www.ncbi.nlm.nih.gov/pubmed/27093998 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016 |
_version_ | 1783555695355887616 |
---|---|
collection | PubMed |
description | OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antithymocyte globulin combined with cyclosporine were retrospectively analyzed. Hematopoietic responses to IST and long-term survival were statistically analyzed for VSAA patients in different ANC subgroups. RESULTS: Pre-IST ANC=0.05×10(9)/L acted as the best cutoff level to predict IST response at 3, 6 months. For 145 VSAA patients, early death rate was 13.4% (11/82) vs 1.6% (1/63), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group (P<0.05). Hematopoietic response rates to IST was 22.0% vs 54.0% (P=0.000) at 3 months, 34.1% vs 63.5% (P=0.000) at 6 months; the overall five-year survival rate was only (62.5±5.4) % vs (91.4±3.7) % (P=0.000) and five-year event-free survival rate was (42.3±5.5) % vs (63.1±6.5) % (P=0.003), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group. CONCLUSION: VSAA patients with extremely low ANC (≤0.05×10(9)/L) had high early death rate and with very low response rate to frontline IST and poor survival, so it is urgent to seek for the alternative frontline therapy that will bring faster and better outcome for these patients. |
format | Online Article Text |
id | pubmed-7343096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73430962020-07-16 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze early hematopoietic response and long-term survival of very severe aplastic anemia (VSAA) patients with different absolute neutrophil counts (ANC) after frontline immnunosuppressive therapy (IST). METHODS: Clinical data and outcome of 145 VSAA patients treated with rabbit antithymocyte globulin combined with cyclosporine were retrospectively analyzed. Hematopoietic responses to IST and long-term survival were statistically analyzed for VSAA patients in different ANC subgroups. RESULTS: Pre-IST ANC=0.05×10(9)/L acted as the best cutoff level to predict IST response at 3, 6 months. For 145 VSAA patients, early death rate was 13.4% (11/82) vs 1.6% (1/63), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group (P<0.05). Hematopoietic response rates to IST was 22.0% vs 54.0% (P=0.000) at 3 months, 34.1% vs 63.5% (P=0.000) at 6 months; the overall five-year survival rate was only (62.5±5.4) % vs (91.4±3.7) % (P=0.000) and five-year event-free survival rate was (42.3±5.5) % vs (63.1±6.5) % (P=0.003), respectively, in the ANC≤0.05×10(9)/L group and ANC>0.05×10(9)/L group. CONCLUSION: VSAA patients with extremely low ANC (≤0.05×10(9)/L) had high early death rate and with very low response rate to frontline IST and poor survival, so it is urgent to seek for the alternative frontline therapy that will bring faster and better outcome for these patients. Editorial office of Chinese Journal of Hematology 2016-04 /pmc/articles/PMC7343096/ /pubmed/27093998 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title_full | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title_fullStr | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title_full_unstemmed | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title_short | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
title_sort | 不同中性粒细胞计数阈值下极重型再生障碍性贫血免疫抑制治疗的血液学反应及生存研究 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343096/ https://www.ncbi.nlm.nih.gov/pubmed/27093998 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.016 |
work_keys_str_mv | AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū AT bùtóngzhōngxìnglìxìbāojìshùyùzhíxiàjízhòngxíngzàishēngzhàngàixìngpínxuèmiǎnyìyìzhìzhìliáodexuèyèxuéfǎnyīngjíshēngcúnyánjiū |